Trade Gilead ^GILD

NBC Securities Inc. Acquires 10,296 Shares of Gilead Sciences, Inc. $GILD

Gilead Sciences, Inc. $GILD is Kerusso Capital Management LLC's 6th Largest Position

Gilead Sciences, Inc. $GILD Stake Boosted by China Universal Asset Management Co. Ltd.

Kerusso Capital Management LLC Grows Stock Position in Gilead Sciences, Inc. $GILD - Daily Political

Gilead Sciences (GILD) Ends Losing Streak with 0.56% Gain

Has Gilead Sciences (GILD) Pulled Back Enough To Revisit Its Valuation Story?

Gilead Sciences, Inc. $GILD Holdings Decreased by Ruffer LLP

West Michigan Advisors LLC Purchases 4,173 Shares of Gilead Sciences, Inc. $GILD - Stock Observer

Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Weakness And Long Term Gains

KLP Kapitalforvaltning AS Trims Stock Holdings in Gilead Sciences, Inc. $GILD - Daily Political

Merck (MRK) Receives FDA Approval for Idvynso, a New HIV Treatment

Zacks Research Predicts Lower Earnings for Gilead Sciences

Ticino Wealth Buys Shares of 7,568 Gilead Sciences, Inc. $GILD - Daily Political

Population pharmacokinetics of tenofovir alafenamide delivered via an annual subdermal implant in South African women

Zurcher Kantonalbank Zurich Cantonalbank Purchases 19,741 Shares of Gilead Sciences, Inc. $GILD - Markets Daily

Gilead Sciences, Inc. $GILD Stake Lowered by Miller Howard Investments Inc. NY

Gilead Sciences, Inc. $GILD Shares Sold by Miller Howard Investments Inc. NY - Stock Observer

Gilead Deepens Oncology Reach And HIV Prevention With Arcellx And Lenacapavir

Gilead Sciences, Inc. $GILD Shares Acquired by AE Wealth Management LLC

Gilead Leans Further Into Oncology With Arcellx And Tubulis Deals

Gilead Sciences, Inc. $GILD Shares Bought by GF Fund Management CO. LTD.

Gilead Sciences, Inc. $GILD Position Raised by Asset Management One Co. Ltd.

The Goldman Sachs Group Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - Stock Observer

Citi Raises Gilead (GILD) Price Target Ahead of Q1 Biopharma Preview

How Investors Are Reacting To Gilead Sciences (GILD) Expanding No‑Profit Lenacapavir Access Globally

Jim Cramer on Gilead Sciences: "I'd Hold On to It"

GILD: Oncology Deals And HIV Franchise Will Support Future Earnings

Gilead Sciences (NASDAQ:GILD) Given New $130.00 Price Target at The Goldman Sachs Group

Morgan Stanley Adjusts Gilead Sciences, Inc. (GILD) Outlook Ahead of Q1 Earnings

Pharmaceutical Stocks To Follow Now - April 17th - Stock Observer

Mirae Asset Global Investments Co. Ltd. Grows Stake in Gilead Sciences, Inc. $GILD

Gilead Sciences (NASDAQ:GILD) Insider Johanna Mercier Sells 3,000 Shares - Markets Daily

Farther Finance Advisors LLC Raises Holdings in Gilead Sciences, Inc. $GILD

Gilead Sciences, Inc. $GILD Stock Holdings Lowered by Assetmark Inc.

Mirae Asset Global Investments Co. Ltd. Raises Stock Position in Gilead Sciences, Inc. $GILD - Stock Observer

Gilead Sciences (NASDAQ:GILD) CFO Andrew Dickinson Sells 3,000 Shares of Stock - Stock Observer

Gilead Sciences patents new GTPase KRAS G12D inhibitors | BioWorld

Andrew Dickinson Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Insider Selling: Gilead Sciences (NASDAQ:GILD) Insider Sells $422,880.00 in Stock

Gauging Gilead Sciences (GILD) Valuation After Strong Multi‑Year Shareholder Returns

KBC Group NV Has $398.25 Million Stake in Gilead Sciences, Inc. $GILD

Zacks Research Expects Lower Earnings for Gilead Sciences

Gilead Sciences (NASDAQ:GILD) Price Target Raised to $165.00 - Zolmax

Gilead's Lenacapavir Access Push And Pricing Protests Shape HIV Outlook

Gilead Sciences (GILD) to Release Quarterly Earnings on Thursday

Pursuit Wealth Management LLC Acquires Shares of 5,826 Gilead Sciences, Inc. $GILD - Daily Political

Lbp Am Sa Has $27.41 Million Stock Position in Gilead Sciences, Inc. $GILD - Daily Political

Cramer's lightning round: Nokia still has room to run

Bingham Private Wealth LLC Invests $1.42 Million in Gilead Sciences, Inc. $GILD

Zacks Research Predicts Weaker Earnings for Gilead Sciences - Daily Political

- Additional Commitment will Expand Access to Lenacapavir to

Is It Too Late To Consider Gilead Sciences (GILD) After Its Strong 1 Year Share Price Run?

Gilead Sciences, Inc. $GILD Shares Purchased by Patton Fund Management Inc. - Markets Daily

1 Profitable Stock for Long-Term Investors and 2 Facing Challenges

Patton Fund Management Inc. Grows Position in Gilead Sciences, Inc. $GILD - Stock Observer

Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer

Morgan Stanley Boosts Gilead (GILD) Outlook on Updated Biopharma Models

Gilead Sciences (NASDAQ:GILD) Given New $165.00 Price Target at Citigroup

Gilead Sciences, Inc. $GILD Shares Sold by Old North State Wealth Management LLC - Markets Daily

Gilead (GILD), Tempus AI (TEM) Expand Multi-Year Oncology R&D Collaboration

How Investors Are Reacting To Kymera Therapeutics (KYMR) Gilead Option Exercise And US$45M Milestone

Massachusetts Financial Services Co. MA Grows Holdings in Gilead Sciences, Inc. $GILD - Stock Observer

Sumitomo Mitsui Trust Group Inc. Sells 60,405 Shares of Gilead Sciences, Inc. $GILD - Daily Political

Robeco Institutional Asset Management B.V. Sells 108,349 Shares of Gilead Sciences, Inc. $GILD - Daily Political

Does Tempus AI's (TEM) Deeper Gilead Tie Mark a Shift in Its Platform Strategy?

Ritholtz Wealth Management Acquires 7,865 Shares of Gilead Sciences, Inc. $GILD

Gilead Sciences (NASDAQ:GILD) Given New $115.00 Price Target at Cantor Fitzgerald - Stock Observer

Tempus AI (TEM) Stock Surges on Expanded Gilead Partnership for Oncology Data Platform

Tempus AI Gilead Expansion Deepens Role In Oncology Drug Development

Gilead Sciences (NASDAQ:GILD) Price Target Raised to $175.00 - Daily Political

Gilead Sciences (GILD) to Acquire Tubulis for $5B to Strengthen Oncology Pipeline

Jackson Square Capital LLC Takes Position in Gilead Sciences, Inc. $GILD - Markets Daily

Company Website: https://tempus.com CHICAGO -- (Business W

Gilead Sciences, Inc. $GILD Shares Purchased by OFI Invest Asset Management - Markets Daily

How EQT's Buybacks and Tubulis Exit May Reshape EQT (OM:EQT) Investors' Capital Recycling Story

OFI Invest Asset Management Acquires 470,804 Shares of Gilead Sciences, Inc. $GILD

8,451 Shares in Gilead Sciences, Inc. $GILD Bought by Jackson Square Capital LLC

Gilead Sciences, Inc. (NASDAQ:GILD) Receives $157.62 Average Price Target from Analysts - Markets Daily

Gilead Agrees $5 Billion Tubulis Acquisition To Expand Cancer Drug Pipeline

Gilead Sciences, Inc. $GILD Shares Sold by Yousif Capital Management LLC - Markets Daily

Sivik Global Healthcare LLC Buys Shares of 25,000 Gilead Sciences, Inc. $GILD

Gilead Tubulis Deal Expands ADC Oncology Pipeline And Valuation Debate

Is Gilead Sciences (GILD) Among the Best Low Volatility Blue Chip Stocks to Buy Now?

Stock Yards Bank & Trust Co. Has $1.80 Million Position in Gilead Sciences, Inc. $GILD - Daily Political

Gilead Sciences Details Tubulis, Ouro, Arcellx Deals as Pipeline Catalyst, 2026 Updates Loom

Is It Time To Reassess Gilead Sciences (GILD) After Its Strong Multi Year Share Price Run

EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion